



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Sunday, November 22, 2009

## Mylan Laboratories

[View the current Mylan Laboratories Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/7312-Mylan+Laboratories.html)

(<http://www.bioportfolio.com/bi corporate/7312-Mylan+Laboratories.html>)

### Contact Details:

**1500 Corporate Drive Suite 400**

**Canonsburg**

**PA**

**15317**

**United States of America**

Tel: 724-514-1800

Fax:

Email: [investor\\_relations@mylan.com](mailto:investor_relations@mylan.com)

Mylan is a global pharmaceutical company with market leading positions in generic pharmaceuticals, transdermal technology and unit dose packaged products. We focus on providing an extensive line of affordable, high quality prescription drugs in traditional and innovative dosage forms, and we enjoy a well-deserved reputation for scientific expertise in creating difficult-to-formulate and high-barrier-to-entry generic products. Mylan operates three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. (all wholly-owned), and has a 71.5% controlling interest in Matrix Laboratories Limited (71.5% owned). Mylan Pharmaceuticals Inc., with locations in Morgantown, W.Va., Caguas, Puerto Rico, and Greensboro, N.C., is a world leader in the research, development, production and marketing of generic pharmaceuticals. Mylan Technologies Inc., located in St. Albans and Swanton, Vt., is a leader in transdermal drug delivery technology and is the largest producer of generic and branded transdermal patches for the U.S. market. UDL Laboratories Inc., with locations in Rockford, Ill., and Sugar Land, Texas, is the top U.S.-supplier of unit dose pharmaceuticals to hospitals and other institutions. Mylan also owns a controlling interest in India-based Matrix Laboratories Limited, which provides Mylan with a platform for global expansion and growth. Matrix is the second largest supplier of active pharmaceutical ingredient (API) sourcing and provides expanded marketing capabilities through Docpharma, a Matrix subsidiary that is a primary marketer of branded generics in Europe. Matrix is a public limited company listed on the Bombay Stock Exchange and the National Stock Exchange of India and currently owns, in whole or in part, 12 other facilities and business units located in India, China and South Africa.

### Press Releases on Mylan Laboratories:

[Reportlinker Adds](#)

[Medical Specialty Bags](#)

[- Global Market Trends](#)

20th November,  
2009

Reportlinker

*NEW YORK, Nov. 20 /PRNewswire/  
-- Reportlinker.com announces that a  
new market research report is  
available in its catalogue. Medical  
Specialty Bags - Global Market  
Trends <http://www.reportlinker.com>*

## [Impax Laboratories](#)

### [Drives Stronger](#)

20th November,

IBM

### [Performance with IBM](#)

2009

### [Business Analytics](#)

-- C-level Executive Committee can now easily pull together a single view of net sales, profitability and competitive market share information, helping them to determine whether

## [Merck Receives CHMP](#)

### [Positive Opinion for](#)

20th November,

Merck & Co., Inc.

### [New Fertility](#)

2009

### [Treatment,](#)

### [ELONVA\(R\)](#)

WHITEHOUSE STATION, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Merck & Co., Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has

## [BioForm Medical and](#)

### [Galderma Laboratories](#)

### [Chiefs to Make](#)

19th November,

Orlando Dermatology  
Aesthetic & Clinical  
(ODAC)

### [Opening Keynote](#)

2009

### [Address on Leadership](#)

### [at Orlando](#)

### [Dermatology Aesthetic](#)

### [& Clinical Conference](#)

NEW YORK, Nov. 19 /PRNewswire/ -- The Orlando Dermatology Aesthetic & Clinical (ODAC) conference is proud to welcome two leading executive officers offering their unique perspectives on the state

## [Vernier and Bio-Rad to](#)

### [Offer Enhanced](#)

18th November,

Vernier Software &  
Technology

### [Solutions for](#)

2009

### [Biotechnology](#)

### [Education](#)

Vernier's experience in data analysis combined with Bio-Rad's Biotechnology Explorer (TM) program kits and curricula provide state-of-the-art solutions to biotechnology education  
BEAVERTON,

## BioNews Results for Mylan Laboratories



- [Mylan wins FDA approval for generic acid reflux drug](#)  
*Pharmacy Choice: Nov 13 2009 1:27AM Matching: mylan laboratories*
- [Mylan Inc Subsidiary Matrix Laboratories Receives FDA Approval](#)  
*TransWorldNews: Nov 13 2009 8:33PM Matching: mylan laboratories*
- [Matrix's Lansoprazole approved](#)  
*Pharmacy Europe: Nov 13 2009 11:36AM Matching: mylan laboratories*
- [Matrix Labs gets US FDA nod for Lansoprazole delayed-release caps](#)  
*PharmaBiz: Nov 12 2009 10:32AM Matching: mylan laboratories*
- [Mylan wins FDA approval for generic acid reflux drug](#)  
*Individual.com: Nov 12 2009 6:59PM Matching: mylan laboratories*
- [Mylan Receives FDA Approval For Generic Version Of Prevacid Through Its Subsidiary Matrix Laboratories](#)  
*Medical News Today: Nov 12 2009 6:31PM Matching: mylan laboratories*
- [Mylan Receives FDA Approval for Generic Version of Prevacid\(R\) Through its Subsidiary Matrix Laboratories](#)  
*Philadelphia Business Journal: Nov 11 2009 4:00AM Matching: mylan laboratories*

- [Mylan Receives FDA Approval for Generic Version of Prevacid\(R\) Through its Subsidiary Matrix Laboratories](#)  
*Pharmacy Choice: Nov 11 2009 4:16AM Matching: mylan laboratories*
- [Mylan Inc awarded FDA approval for generic Prevacid DR Capsules -...](#)  
*Zibb: Nov 11 2009 12:19PM Matching: mylan laboratories*
- [Mylan Receives FDA Approval for Generic Version of Prevacid Through its Subsidiary Matrix Laboratories](#)  
*PharmaceuticalProcessing: Nov 11 2009 7:28PM Matching: mylan laboratories*
- [Mylan subsidiary receives FDA approval for its Lansoprazole DR Capsules ANDA](#)  
*News-Medical.Net: Nov 11 2009 6:24AM Matching: mylan laboratories*
- [Mylan Inc awarded FDA approval for generic Prevacid DR Capsules](#)  
*Pharmacy Choice: Nov 11 2009 2:14PM Matching: mylan laboratories*
- [Mylan Inc awarded FDA approval for generic Prevacid DR Capsules](#)  
*TradingMarkets: Nov 11 2009 11:39AM Matching: mylan laboratories*
- [Mylan Inc awarded FDA approval for generic Prevacid DR Capsules](#)  
*M2: Nov 11 2009 11:24AM Matching: mylan laboratories*
- [Mylan's Matrix Laboratories gets FDA approval for generic version of Prevacid](#)  
*Pharmacy Choice: Nov 11 2009 6:35PM Matching: mylan laboratories*

#### Mylan Laboratories Clinical Trials:



- [A Phase II/III Study of Cysteamine \(Mercaptoethylamine\) and Zidovudine for the Treatment of HIV Disease](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

